Brivanib - Analysis and Market Forecasts from 2013 to 2020

Description: Brivanib – Analysis and Market Forecasts from 2013 to 2020

Summary

GlobalData's pharmaceuticals report, “Brivanib – Analysis and Market Forecasts from 2013 to 2020” provides Brivanib sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Liver Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Brivanib including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Brivanib including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2013-2020 for Brivanib in the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Contents:

1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Liver Cancer Market
2.2 Epidemiology
2.3 Etiology
2.3.1 Hepatitis B Infection
2.3.2 Hepatitis C Infection
2.3.3 Alcohol
2.3.4 Aflatoxin B1
2.3.5 Hemochromatosis
2.3.6 Diabetes and Obesity
2.3.7 Cirrhosis
2.4 GlobalData Report Guidance
3 Liver Cancer : Market Characterization
3.1 Liver Cancer Market
3.2 Liver Cancer Market Forecasts and CAGR
3.3 Drivers for the Liver Cancer Market
3.3.1 High Incidence
3.3.2 High Mortality
3.3.3 Large Unmet Need
4 Tumor–Node–Metastases (TNM) Classification of Liver Cancer
5 Brivanib
5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.4 Indications of Brivanib
5.5 Factors Affecting Sales of Brivanib
5.5.1 Oral Administration
5.5.2 Second Line Treatment
5.5.3 Adjuvant to TACE (Transcatheter Arterial Chemoembolization)
5.5.4 Dual Selective Inhibition
5.6 Drug Risk Benefit Score
5.6.1 Efficacy
5.6.2 Safety
5.6.3 Compliance
5.6.4 Dosing Convenience
5.7 Intensity of Competition
5.8 Sales forecast
5.8.1 Target patient Pool of Brivanib
5.8.2 Dosing
5.8.3 Market Penetration
5.8.4 Annual Cost of Therapy
5.8.5 Sales Projections of Brivanib
6 Liver Cancer Market: Appendix
6.1 Market Definitions
6.2 List of Abbreviations
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Forecasting
6.3.4 Number of Patients Approved to take the Drug
6.3.5 Net Penetration of Drug
6.3.6 Net Annual Dosing
6.3.7 Annual Cost of Therapy
6.3.8 Primary Research
6.3.9 Expert Panels
6.4 Drug Sales Estimates Model
6.5 Contact Us
6.6 Disclaimer
6.7 Sources

1.1 List of Tables
Table 1: Liver Cancer, Incidences and Mortality, 2008–2030
Table 2: Drug Risk Benefit Score of Brivanib
Table 3: Brivanib, Liver Cancer, The US, EU–5 and Japan Sales Forecasts ($m), 2013–2020
Table 4: Brivanib, Liver Cancer, The US, Sales Forecasts ($m), 2013–2020
Table 5: Brivanib, Liver Cancer, The UK, Sales Forecasts ($m), 2013–2020
Table 6: Brivanib, Liver Cancer, France, Sales Forecasts ($m), 2013–2020
Table 7: Brivanib, Liver Cancer, Germany, Sales Forecasts ($m), 2013–2020
Table 8: Brivanib, Liver Cancer, Italy, Sales Forecasts ($m), 2013–2020
Table 9: Brivanib, Liver Cancer, Spain, Sales Forecasts ($m), 2013–2020
Table 10: Brivanib, Liver Cancer, Japan, Sales Forecasts ($m), 2013–2020

1.2 List of Figures
Figure 1: Fatality = [% Distribution of Incidence] – [% Distribution Mortality] of Most Common Cancers
Figure 2: Liver Cancer, Global, Market Size Forecast ($m), 2010–2020
Figure 3: Liver Cancer, Worldwide, Incidence (in millions), 2008–2030
Figure 4: Oncology, Worldwide, Incidence (in millions), 2008–2030
Figure 5: Liver Cancer, Worldwide, Mortality (in millions), 2008–2030
Figure 6: Classification of Liver Cancer
Figure 7: Clinical Trials Results, Brivanib
Figure 8: Drug Model Diagram of Brivanib
Figure 9: Brivanib, Liver Cancer, The US, EU-5 and Japan, Sales Forecasts ($m), 2013–2020
Figure 10: Brivanib, Liver Cancer, The US, Sales Forecasts ($m), 2013–2020
Figure 11: Brivanib, Liver Cancer, The UK Sales Forecasts ($m), 2013–2020
Figure 12: Brivanib, Liver Cancer, France, Sales Forecasts ($m), 2013–2020
Figure 13: Brivanib, Liver Cancer, Germany, Sales Forecasts ($m), 2013–2020
Figure 14: Brivanib, Liver Cancer, Italy, Sales Forecasts ($m), 2013–2020
Figure 15: Brivanib, Liver Cancer, Spain, Sales Forecasts ($m), 2013–2020
Figure 16: Brivanib, Liver Cancer, Japan, Sales Forecasts ($m), 2013–2020
Figure 17: Distribution of Brivanib Sales in Major Countries, 2020
Figure 18: Drug Model Diagram
Figure 19: Patients Approved for the Drug

Ordering:  
Order Online - [http://www.researchandmarkets.com/reports/1934524/](http://www.researchandmarkets.com/reports/1934524/)
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Brivanib - Analysis and Market Forecasts from 2013 to 2020
Web Address: http://www.researchandmarkets.com/reports/1934524/
Office Code: SCD2LP9P

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World